Historically, IFN has been used as a first-line therapy for patients with chronic-phase CML who are not eligible for allogeneic stem cell transplantation; this was the case until introduction of the potent BCR/ABL tyrosine kinase inhibitor imatinib mesylate. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.